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Abstract  
The prevalence of autism spectrum disorder (ASD) in many genetic disorders is well 
documented but not as yet in Mucopolysaccharidosis type III (MPS III). MPS III is a 
recessively inherited metabolic disorder and evidence suggests that symptoms of ASD present 
in MPS III. This systematic review examined the extant literature on the symptoms of ASD in 
MPS III and quality assessed a total of 16 studies. Results indicated that difficulties within 
speech, language and communication consistent with ASD were present in MPS III, whilst 
repetitive and restricted behaviours and interests were less widely reported. The presence of 
ASD-like symptoms can result in late diagnosis or misdiagnosis of MPS III and prevent 
opportunities for genetic counselling and the provision of treatments. 
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Mucopolysaccharide diease type III (MPS III) belongs to a group of seven rare inherited 
metabolic disorders characterised by the deficiency of one of the lysosomal enzymes catalysing 
the degradation of glucosaminoglycans (GAG) or mucopolysaccharides. This deficiency 
results in abnormal accumulation of GAG in the lysosomes which consequently results in 
cellular damage and multi-systemic disease. Mucopolysaccharide disease type III (MPS III or 
Sanfilippo syndrome) is the most common of the mucopolysaccharidoses (Miekle, Hopwood, 
Clague & Carey, 1999). Four subytpes of MPS III have been indentified with their underlying 
genotypes and biochemistry established: MPA IIIA, IIIB, IIC and IIID (Valstar, Ruijter, van 
Diggelen, Poorthuis & Wijburg, 2008). Subtype A is the most prevalent in the UK, subtype B 
is less common and subtypes C and D are rare (Cleary & Wraith, 1993). Similar rates are 
documented internationally (Valstar et al, 2008), although subtype B is known to be more 
common in South East Europe (Heron et al, 2010). Clinically, there is very little difference 
between the subtypes, but subtype A is known to follow a more severe course (Van De Kamp, 
Niermeijer, Von Figura, & Giesberts, 1981) and subtype C a more attenuated course (Ruijter 
et al, 2008).   
Evidence suggests that  many children with MPS III present with symptoms of  Autism 
Spectrum Dmisdiagnisorder (ASD), such as language delay (Buhrman, Thakkar, Poe & 
Escolar, 2013) and impaired social communication (e.g., Shapiro et al, 2016). According to 
Rumsey et al (2014), symptoms of ASD are acquired (i.e., symptoms emerge at a later age 
following an otherwise typical development initially) in MPS III, suggestive of an atypical 
profile of ASD, as opposed to idiopathic ASD. The presentation of ASD-like symptoms has 
resulted in children with MPS III being misdiagnosed (‘misdiagnosis’- a term used by studies 
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to describe an instance whereby ASD or another neurodevelopmental diagnosis has 
masqueraded a diagnosis of MPS III) with ASD and late diagnoses of MPS III (Wijburg, 
Wegzryn, Burton & Tylki-Szymanska, 2013). This has implications for genetic counselling 
and forestalls possible interventions for MPS III (Deshpande & Sathe, 2015). 
Previous reviews have identified the prevalence of ASD in a range of genetic 
syndromes (Richards, Jones, Groves, Moss & Oliver, 2016)  and demonstrated  significant 
associations between ASD and other genetic developmental disorders (Moss & Howlin, 2009). 
Previous reviews have identified the prevalence of ASD in a range of genetic syndromes 
(Richards, Jones, Groves, Moss & Oliver, 2016)  and demonstrated  significant associations 
between ASD and other genetic developmental disorders (Moss & Howlin, 2009). In their 
review of 42 studies of other genetic disorders,  including., Fragile X syndrome, Rett syndrome, 
Down syndrome, Tuberous Sclerosis Complex and phenylketonuria , Moss and Howlin (2009) 
indicated that symptoms of ASD are signficantly more likely to occur in individuals with such 
disorders than in the general population.. Such symptoms may be present in the absence of a 
formal diagnosis of ASD and this supports the distinction between syndromic and non-
syndromic variants of ASD. Understanding the overlap between ASD and genetic syndromes 
could potentially enable the genetic and biological pathways that underlie idiopathic ASD to 
be identified. 
Despite the reviews identified above, no review to date has focused specifically on the 
mucopolysaccharidoses. Although Wijburg et al (2013) summarised the misdiagnosis of MPS 
III as ASD, to date, there has been no systematic review of the symptoms of ASD in MPS III. 
Consequently, this review aimed to a) identify the extant literature on the symptoms of ASD 
in individuals with MPS III, b) identify which symptoms are observed and c) identify any 
common implications of ASD-like symptoms and d) assess the quality of included studies. 
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Method 
A systematic search was conducted using Ovid to review five databases from inception 
to February 19th, 2017 PsycInfo, Embase, Medline, Global Health, and Health and Psychosocial 
Instruments. In addition, the references of included studies were hand-searched for relevant 
articles. 
 
Search terms 
Search terms included ASD OR Autism OR Autis* OR pervasive developmental 
disorder OR communication difficulties OR social difficulties OR language delay OR speech 
delay OR delay OR behaviour problems OR behavioural problems OR restricted behaviour OR 
repetitive behaviour” AND “Sanfilippo Syndrome OR Mucopolysaccharidosis OR 
Mucopolysaccharide disorder OR Mucopolysaccharide disease OR Mucopolysaccharide 
disease type III”. The search process, based on Preferred Reporting Items for Systematic 
Reviews and Meta-Analyses guidelines (PRISMA) (Moher, Liberati, Tetzlaff & Altman, 2009) 
is outlined in Figure 1. 
 
[insert Figure 1 about here] 
 
Inclusion and exclusion criteria 
Inclusion criteria for the current review were studies published in English, which 
focused on MPS III and reported symptoms consistent with ASD (e.g., language or speech 
delay, communication difficulties, social difficulties, repetitive or restricted behaviour), whilst 
the following exclusion criteria were applied: non-English language, reviews and mini-
reviews, studies which focused on other types of mucopolysaccharidoses, reports of behaviours 
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inconsistent with ASD or a lack of detail surrounding behaviour and biological or genetic 
studies, i.e. reports on the biological rather than behavioural aspects of MPS III. 
 
Quality assessment tool 
The Quality Assessment Tool for Studies with Diverse Designs (QATSDD) was 
selected (Sirriyeh, Lawton, Gardner & Armitage, 2011), because it has good reliability and 
validity (Fenton, Lauckner & Gilbert, 2015) and because the methodologies used in these 
studies were expected to be diverse. Each of the 16 QATSDD items is rated on a 4-point-scale 
from “not at all” (0) to “complete” (3) and from which an overall quality rating of 0-42 can be 
computed. Consistent with the tool guidance (Sirriyeh et al, 2011), percentage scores were 
calculated (e.g., the total score was divided by the maximum potential score and multiplied by 
100) reported, with studies scoring over 75% considered to be of “high” quality, those between 
50% and 75% “good”, 25%–50% “moderate” and below 25% as “poor”. The first author (CW) 
and a peer colleague, independent to the study team, collaboratively rated all studies. 
 
Results 
Selection of studies 
A total of 16 studies (see Table 1) was identified for inclusion in the current review that 
reported on a total of 620 participants with diagnoses of MPS III. One study (Paper 15) 
involved two control groups, MPS I-Hurler Syndrome with eight participants and MPS IIIA 
with nine participants. Of the 620 participants with MPS III (see Table 2), 286 had confirmed 
sub-type A (MPS IIIA), 124 sub-type B (MPS IIIB), 56 had sub-type C (MPS IIIC), nine had 
sub-type D (MPS IIID) and 145 did not specify which sub-type. Four of the studies originated 
from the USA (Papers 2, 9, 11 and 15). Case report studies (Papers 3, 7, 9, 12, 13, 14 and 16) 
originated from Saudi Arabia, the Netherlands, Poland, Israel, India and Turkey and cross-
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sectional studies (Papers 1, 2, 4, 5, 6, 8 and 10) originated from Denmark, the UK, the 
Netherlands, Sweden, France and Spain.  
 
[Insert Table 1 about here] 
 
The studies varied in their participant descriptions (see Table 2). All studies reported 
gender and age; however, only nine studies provided information surrounding ethnicity or 
nationality (Papers 3, 5, 6, 7, 8, 9, 12, 13 and 16). Half of the studies (Papers 1, 5, 7, 8, 9, 12, 
13 and 16) provided additional data regarding the relationship between participants and their 
families. Paper 1 noted that 41 of 73 participants were from sibling relationships and Paper 8 
reported on 70 of 111 participants who were from multiplex1 families. Consanguinity was 
another factor to which some studies referred to. Paper 5 highlighted that six of their 20 
participants were from consanguineous families and Paper 13 described the case of a child from 
a consanguineous family. Whilst these two studies noted consanguinity, other studies (Papers 
7, 9, 12 and 16) explicitly stated that participants were from non-consanguineous families.  
Of the 16 studies, seven studies (Papers 1, 2, 4, 5, 6, 8 and 10) described and analysed 
cognitive, behavioural and motor difficulties within MPS III (Table 2). Seven of the studies 
were case reports (Papers 3, 7, 9. 12, 13, 14 and 16) which described presentations of MPS III 
and issues pertaining to its diagnosis and misdiagnosis. Paper 15 compared participants with 
MPS IIIB to participants with MPS IIIA and MPS IH (Hurler syndrome) and two studies 
(Papers 11 and 15) formally assessed symptoms of ASD in participants with MPS IIIA and 
MPS IIIB. 
 
                                                          
1
 A family in which a person diagnosed with a complex genetic disorder has a 1st- or 2nd-degree relative with 
the same diagnosis 
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[Insert Table 2 about here] 
 
Quality ratings 
Scores on the QATSDD ranged between 22% and 74% with a mean score of 49% (see 
Table 3).  
As previously mentioned, almost half of the studies (n=7) reviewed were single case 
reports (Papers 3, 7, 9. 12, 13, 14 and 16); consequently, these were mostly rated as being of 
moderate methodological quality.  In contrast, other studies were group-level studies (Papers 
5, 11 and 15), with the three highest methodological quality studies coming from the USA 
(Papers 2, 11 and 15). Paper 16 obtained the lowest rating owing to a lack of information 
surrounding the choice of data collection, brief reference to the theoretical framework, 
justification for method and analysis and a lack of reference to the study’s strengths and 
limitations. In all 16 studies there was a lack of discussion surrounding the involvement of 
service users in their study designs.  
Across the studies, seven obtained a moderate score for quality (Papers 1, 3, 5, 6, 12, 
13 and 14) and eight were deemed to be of good quality (Papers 2, 4, 7, 8, 9, 10, 11 and 15).  
There was no observed relationship between quality and year of publication. Furthermore, as 
can be expected cross-sectional designs scored consistently better than the other designs 
reviewed. As this is the first review of the literature surrounding the symptoms of ASD in MPS 
III, all studies were retained to present a comprehensive picture of the available research. 
 
[Insert Table 3 about here] 
 
Symptoms of ASD 
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All of the 16 studies referred to behaviours characteristic of ASD, with ten studies 
(Papers 3, 5, 6, 7, 8, 11, 12, 13, 14 and 15)) making a specific reference to ASD (Table 1). 
However, whilst these studies made specific reference to ASD, some case reports described 
observed behaviours in detail (Papers 9 and 14). In addition, some studies used the term 
‘autistic features’ or ‘autistic like’ and failed to provide detailed descriptions (Papers 3,7 and 
13). The lack of detailed descriptions was also noted in some of the cross-sectional studies 
(Papers 2, 4, 6, 8 and 10). For example, a relative strength of Paper 8 was its larger sample size 
when compared to the other studies yet it did not describe symptoms of ASD in great detail.  
When ASD-related behaviours and symptoms were specified and described in studies, 
these were categorised as: 
 Speech, language and communication difficulties: Despite differing sample sizes, study 
designs and quality ratings, all 16 studies consistently reported difficulties with speech, 
language and communication (Table 2) with nine studies making explicit reference to this as a 
feature of ASD (Papers 3, 5, 7, 8, 11, 12, 13, 14 and 15). Difficulties in this domain included 
delayed language and speech development, limited vocabulary, no speech, echolalia, variable 
or no eye contact and impaired communication skills. The studies differed in reporting of age 
of onset of these behaviours, which were primarily reported as emerging after 18 months.  
When participants were assessed with a ‘gold-standard’ ASD assessment tool, the Autism 
Diagnostic Observation Schedule (ADOS) (Lord, Rutter, DiLavire & Risi, 1999), they 
consistently met ADOS diagnostic criteria on communication domains (Papers 11 and 15).   
   Repetitive and restricted behaviour: Two case reports reported repetitive and restricted 
behaviours. Paper 7 described a female participant (aged 57 years) with MPS IIIB who 
exhibited repetitive behaviour during adulthood, whereas Paper 14 described a seven-year-old 
girl (sub-type of MPS III not determined), presenting with repetitive hand clapping and head 
banging from the age of two years. However, neither study used standardised assessment tools. 
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Two larger studies with sample sizes of 21 (Paper 11) and ten (Paper 15) utilised the ADOS, 
but reported little repetitive or restricted behaviour. 
Social difficulties: Ten studies observed social difficulties typical of an ASD 
presentation and these included aggression in social situations, peer difficulties and difficulties 
making personal contacts, social immaturity and impaired social interaction (Papers 1, 2, 3, 4, 
5, 7, 8, 9, 11 and 14). As previously noted, not all studies adequately identified the age of the 
emergence of these behaviours, but those that did highlighted that these behaviours were 
evident from the age of three years. Four of the ten studies (Papers 2, 4, 11 and 15) used 
standardised assessment tools, such as the ADOS and Rutter’s parent checklist (Rutter, Graham 
& Yule, 1970), to formally assess for such behaviours, but the remaining six studies a) failed 
to identify how behaviours were assessed and b) failed to identify the assessment tool or c) 
relied on professional or parent impression. 
 
Diagnosis of ASD  
As previously mentioned, two studies (Papers 11 and 15) utilised the ADOS to assess 
behaviours of children with confirmed diagnoses of MPS IIIA and MPS IIIB; both studies were 
rated as having good methodological quality. Paper 11 concluded that 13 of the 21 children 
aged between 1.8 to 8.8 years with MPS IIIA met diagnostic criteria for ASD (as measured by 
module 1 of the ADOS) and that this was strongly associated with age; 11 children aged over 
3.8 years met ADOS diagnostic criteria, compared with only two of ten children aged less than 
3.8 years meeting ADOS diagnostic criteria. Paper 15 examined ASD in children with MPS 
IIIB and concluded that nine of their ten participants met ADOS criteria for ASD between the 
ages of six and 24 years. Both studies reported increased incidences of social/affective 
behaviour than restricted or repetitive behaviour. As part of their case reports, Paper 9 and 
Paper 15 described participants who presented with hyperactivity, poor social interactions and 
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repetitive behaviour who consequently received diagnoses of pervasive developmental 
disorder prior to receiving a diagnosis of MPS III.  In a large study of MPS III participants, 
Paper 8 noted “autism related symptoms” at time of diagnosis of MPS III in 66% of the UK 
MPS III population (n=126) and in 76% of the French MPS III population (n=128), but did not 
state whether any formal diagnoses of ASD had been made. 
 
Method of behavioural assessment  
Studies that obtained higher scores on the QATSDD were noted to utilise formal 
questionnaires, standardised assessment tools and reported reliability and validity. Only two of 
the studies (Papers 11 and 15) assessed symptoms of ASD formally using the Autism 
Diagnostic Observation Schedule (ADOS) which was a strength of these studies. These studies 
more reliably and validly identified symptoms of ASD in individuals with MPS III.  Paper 2 
reported on the use of several validated and reliable assessment tools, including the Bayley 
Scale of Infant Development (Bayley, 1969), the Stanford-Binet Intelligence Scale (Terman & 
Merrill, 1973) and the Vineland Social Maturity Scale (Doll, 1965). The findings of this paper 
suggested that children with MPS III begin to deteriorate cognitively between the ages of 3.5 
and 6.5 years, lose language by age 8 years and demonstrate self-stimulatory behaviour and 
experience peer difficulties (Nidiffer & Kelly,.1983).  Whilst these tools do not specifically 
assess for ASD or repetitive behaviour and restricted interests, they do examine behaviours, 
such as language and social difficulties. A significant weakness of some studies (Papers 7 and 
9) was failing to identify how behaviours were assessed at all, whereas other studies (Papers 6, 
12, 13, 14 and 16), often of lesser quality (as assessed by the QATSDD) than the above-
mentioned studies, referred to clinician and parent observation, impression and reports, which 
resulted in less valid conclusions and less robust study designs.  
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Implications of symptoms of ASD 
Misdiagnosis: Seven of the 16 studies (Papers 3, 5, 6, 9, 12, 13 and 16) reported initial 
misdiagnosis (Table 2) including misdiagnoses of ASD, Attention Deficit Hyperactivity 
Disorder (ADHD), acquired language disorder and intellectual disability (reported as ‘mental 
retardation’). Such misdiagnoses were primarily observed in single-case reports and illustrated 
the phenomenological overlap between the behavioural phenotype of these disorders and MPS 
III.  
Late diagnosis:  Seven of the 16 studies (Papers 2, 4, 5, 6, 7, 9 and 10) noted that a possible 
initial focus on problematic behaviour and developmental delay resulted in late diagnoses of 
MPS III. The larger sample sizes in five of these seven studies (Papers 2, 4, 5 and 6) suggest 
that this can be taken as a relatively reliable and consistent finding across presentations of MPS 
III. Three of the seven studies (Papers 5, 10 and 15) noted that sub-types MPS IIIB and IIIC 
were prone to late diagnosis owing to slow progression and attenuated phenotypes. 
 
Discussion 
Previous reviews have identified the risk of symptoms of ASD in genetic syndromes 
(e.g., Moss & Howlin, 2009; Richards, Jones, Groves, Moss & Oliver, 2016). Despite the 
varying methodological quality of some of the studies included in this review, the current 
systematic review expands on Moss and Howlin’s (2009) review of seven other genetic 
syndromes by also noting the presence of symptoms of ASD in individuals with MPS III. Ten 
of the 16 studies reviewed made specific references to ASD in MPS III, referring broadly to 
“autistic features”, specifically to assessment of ASD and noting incidences of its diagnosis 
prior to diagnoses of MPS III. Speech, language and communication difficulties were 
consistently reported in all of the studies under review, repetitive and restricted behaviour less 
so. According to Rumsey et al (2014), symptoms of ASD are acquired in MPS III and evidence 
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from this review is suggestive of an atypical profile of ASD-like symptoms in MPS III yet 
cannot be concluded given the varying levels of detail reported in included studies, small 
sample sizes and varying methods of behavioural assessment. There was no consistent 
reporting of the onset of these speech, language and communication difficulties, but in line 
with a recent review that examined and reviewed the behaviours of 46 children with MPS IIIA 
(Buhrman et al, 2013), there was some indication that these difficulties were observed from 
18-24 months.  
Studies varied in their methodology surrounding the assessment of behaviours 
considered to be ASD and only two studies used a ‘gold-standard’ tool for assessing ASD, the 
ADOS. When this was used, 13 of 21 participants with MPS IIIA and nine of ten participants 
with MPS IIIB met ADOS diagnostic criteria for ASD.  Similarly to Wijburg and colleagues 
(2013), this review highlighted the implications of misdiagnosis and late diagnosis of MPS III. 
Early diagnosis of MPS III can be challenging (Bodamer, Giugliani & Wood, 2014), partly as 
the result of the wide clinical variability in MPS III but also because clinicians tend to focus 
on the behavioural and developmental issues that are the initial presenting symptoms of MPS 
III.  
 
Clinical implications 
There is overlap between the behavioural phenotypes of both ASD and MPS III, 
particularly in the domains of speech, language, communication and social difficulties. When 
these behaviours occur alongside other physical or developmental abnormalities, clinicians 
should consider screening for MPS III to allow for early identification and diagnosis. In 
addition, clinicians should pay attention to the presence of sleep difficulties, especially 
complete reversals of day-night rhythms and impaired circadian functioning, facial 
dysmorphisms and recurrent ear, nose and throat infections (Mahon et al, 2014; Valstar et al, 
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2008). Benefits of earlier recognition and diagnosis of MPS III include genetic counselling for 
the family (Nidiffer & Kelly, 1983), increased eligibility for effective treatments to take place 
(Wijburg et al, 2013) and potentially improved quality of life. Recognition of ASD-like 
symptoms, whether idiopathic or associated with genetic disorders of known aetiology, 
warrants the provision of tailored and evidenced behavioural support for individuals with MPS 
III, including interventions that support communication and social skills (see Hare, 2015). 
 
Limitations 
To ensure that all eligible and relevant studies were included in the current review, the 
initial search terms were deliberately kept broad. This strategy was successful in identifying 
250 studies that were subsequently checked against the specific inclusion and exclusion 
criteria. As it was expected that the resultant selection would use a variety of methodologies, 
the quality assessment was undertaken using a measure (the QATSDD) specifically designed 
for assessing diverse designs. The QATSDD was useful in guiding both raters in the 
assessment of included papers but limitations of the tool were noted.  The QATSDD does not 
include a quality assessment indicator for bias, and some indicators for the quality assessment 
lack detail, thus raters can apply them in different ways (Fenton, Lauckner & Gilbert, 2015). 
Collaborative quality assessment was useful in managing this because discrepancies could be 
discussed.  To account for some of the limitations of the QATSDD, some adjustments were 
made to the calculation of the overall quality score to allow for better comparisons between 
studies, but this also means that these scores should be viewed with some caution. 
Many of the studies included in this review had small sample sizes and lacked detail 
regarding symptoms and behaviours characteristic of ASD. Furthermore, almost half of the 
studies included were case reports and given the bias inherent in case study designs, readers 
are encouraged to carefully consider  all information and conclusions drawn from these 
  
 
 
14 
studies. Although this approach limits the strength of the conclusions drawn from the studies, 
it was necessary to include these because they are reflective of the current research and 
literature within MPS III. 
 Individuals with MPS III experience deteriorations in intellectual functioning (Grant 
et al, 2012) and there is an increased risk of co-occurring ASD in individuals with intellectual 
disability (Schieve, Clayton, Durkin, Wingate & Drews-Botsch, 2015). The studies cited in 
this review did not explicitly report on levels of intellectual functioning which should be an 
important consideration when assessing for and diagnosing ASD and consequently this 
should be considered a limitation of this review.  
 
Future directions 
A key limitation of many of the studies reviewed was the small sample sizes which is 
necessarily problematic for inferential statistical analysis, but also common in studies of rare 
disorders (De la Paz et al,  2010). However, this should not prevent research into rare disorders, 
such as MPS III, and sample sizes should be considered with regard to epidemiology of the 
syndrome. Further research could consider the use of a Bayesian approach (Howson & Urbach, 
2005) to statistical inferences in the study design of rare diseases (Billingham, Malotti, 
Pritchard & Steven, 2011), because this enables information gathered from previous studies 
(particularly case studies) to contribute to estimation processes as opposed to the traditional 
hypothesis testing observed in larger samples. 
  All of the studies in the review made reference to behaviour that was typical of ASD 
but not all recognised this and some did not provide further details. Future research should 
detail more robustly the profile of symptoms of ASD in MPS III to understand whether it 
features as idiopathic ASD or simply symptoms of ASD. So far, the evidence suggests that the 
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profile of ASD is largely compiled of speech, language, communication and social difficulties 
with little evidence of restricted or repetitive behaviour.  
Only one of the 16 studies in this review (Shapiro et al, 2016) compared the assessment 
of symptoms of ASD in MPS III with a control group of another syndrome. The gold-standard 
assessments of symptoms of ASD should always include comparison to another syndrome to 
assess the degree of difficulty and comparisons to idiopathic ASD to evaluate the similarities 
and the differences in the profile of behaviour. Future research including this could improve 
our understanding of the psychological constructs associated to ASD in MPS III and their 
developmental trajectory. 
 
Conclusions 
 While the evidence base is neither large nor methodologically robust, this review finds 
evidence that symptoms of ASD are present in individuals with MPS III, specifically within 
the domains of speech, language and communication. Such symptoms can prevent and forestall 
clinical diagnosis of MPS III, resulting in reduced opportunities for genetic counselling and 
effective treatments. As MPS III is a rare disorder, the recommendations arising from this 
review are particularly important because they aim to support the growth of its emerging 
research literature to inform clinical practice. Understanding the development of ASD in MPS 
III could lead to the improved understanding of the neuropathology of MPS III and 
furthermore, a greater understanding of how the related emergence of both ASD and 
neurocognitive decline associated with MPS III could clarify disease progression and the neural 
substrate associated with both. 
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Figure 1: Flowchart demonstrating literature review process 
(MPS – Mucopolysaccharide disease, ASD – Autism Spectrum Disorder 
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Table 1: Included papers  
Paper 
Number 
Author Date Site of study Design 
1 Van de Kamp, Niermeijer, 
Von Figura & Giesberts 
 
1981 Denmark Cross-sectional  
2 Nidiffer & Kelly 
 
1983 America Cross-sectional 
3 Ozand et al 
 
1994 Saudi Arabia Case report 
4 Bax & Colville 
 
1995 United 
Kingdom 
Cross-sectional 
5 Moog et al 
 
2007 Netherlands Cross-sectional 
6 Malm & Mansson 
 
2010 Sweden Cross-sectional 
7 Verhoeven et al 
 
2010 Netherlands Case report 
8 Heron et al 
 
2010 France Cross-sectional 
9 Brady, Trehan, Landis & 
Toro 
 
2013 America Case report 
10 Delgadillo, O’Callaghan, 
Gort, Coll & Pineda  
 
2013 Spain Cross-sectional 
11 Rumsey et al 
 
2014 America Case series 
12 Krawiec et al 
 
2014 Poland Case report 
13 Sharkia et al 
 
2014 Israel Case report 
14 Deshpande & Sathe 
 
2015 India Case report 
15 Shapiro et al 
 
2016 America Case control 
16 Kartal 
 
2016 Turkey Case report 
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Table 2: Reported demographics, symptoms of ASD and findings  
 
Paper 
Number 
Sample 
size  
and  
sub-type 
of MPS 
III 
Age and 
demographics 
Symptoms of 
ASD 
Assessment 
method 
Reference to 
ASD or  
diagnosis of 
ASD 
Findings Quality rating 
score 
1 73 
 
A-36 
B-23 
C-14 
41 of the 73 
were from 
sibships 
 
18 participants 
deceased 
55 participants 
alive 
 
Slow and poor 
speech 
development. 
(pre-age 3.5 
years) 
 
Some never 
learned to speak 
 
Aggression in 
stressful 
situations 
Review of 
medical 
records 
 
No details of 
formal 
assessments 
Reports 
symptoms but 
no reference to 
ASD 
Recognition of 
variability at the 
clinical level is of 
utmost importance for 
disease recognition, 
prognosis and genetic 
counselling 
31% 
(Moderate) 
2 30 
 
* 
Mean age 10 
years 
 
16 female 
14 male 
Deterioration of 
communication 
skills 
 
Language 
problems seen 
at mean age 5.6 
years 
 
Questionnaires 
based on: 
 
Bayley Scale 
of Infant 
Development, 
Stanford-Binet 
Intelligence 
Scale, 
Reports 
symptoms but 
no reference to 
ASD 
Late diagnosis owing 
to focus on problematic 
behaviours resulted in 
no genetic counselling 
and thus further MPS 
III siblings 
69% 
(Good) 
  
 
 
26 
Self-stimulatory 
seen at mean 
age 3. 8 years 
 
Peer difficulties 
seen at mean 
age 3.9 years 
 
Loss of 
social/adaptive 
behaviour (age 
5 years) 
Vineland 
Social 
Maturity Scale 
3 1 
 
D 
Saudi Arabian 
female 
7 years old 
Self-stimulating 
behaviour 
 
Few words 
 
Variable eye 
contact (age 6) 
or no eye 
contact (age 7) 
 
Refers to 
“autistic 
behaviour” but 
no further detail 
(age 6) 
Psychometric 
evaluation 
Reference to 
“autistic like, 
self-stimulating 
behaviour”  
 
No formal 
diagnosis 
Participant presented 
with acquired language 
disorder and failed to 
demonstrate the 
phenotype of MPS III 
44% 
(Moderate) 
4 106 
 
* 
Mean age 8.4 
years  
40 male 
56 female 
Loss of 
language 
 
 
Questionnaire 
based on 
American 
Association of 
Mental 
Reports 
symptoms but 
no reference to 
ASD 
Some children with 
MPS III diagnosed late 
in life due to initial 
presentation as 
overactive retarded 
50% 
(Good) 
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Abnormal 
reaction to 
invasion of 
social space 
Deficiency 
questionnaire 
and Rutter’s 
parent 
checklist 
children by which time 
they had acquired one 
or more similarly 
affected siblings 
 
 
Greater emphasis needs 
to be placed on the 
need for earlier 
diagnosis 
 
5 20 
 
B - 20 
Dutch 
 
Mean age of 43 
years for alive 
participants 
 
6 from 
consanguineous 
family 
 
8 male (2 
deceased) 
12 female (6 
deceased) 
Delayed 
language and 
speech 
development 
 
Stereotypic 
speech 
 
Inability to keep 
up pace of peers 
 
 
No speech or 
unintelligible 
speech 
Hypersensitivity 
to touch and 
sensitive to 
temperature 
 
Observations 
of elderly 
residents with 
Intellectual 
Disability 
completed 
with care 
providers 
and/or parents 
 
Interviews 
with carers 
and family 
Reports 
symptoms and 
refers to ASD 
in one case 
In one patient 
metabolic screening 
was performed because 
of a suspicion of ASD. 
 
IIIB may be diagnosed 
later in life due to a 
normal phenotype and 
because progression is 
slow.  
33% 
(Moderate) 
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One participant 
never spoke 
 
Problems in 
making 
personal 
contacts 
6 22 
 
A - 15 
B - 1 
C – 5 
type not 
determined 
-1 
Ranged 
between 1.2-29 
years 
 
13 male (6 
alive, 7 
deceased) 
9 female (4 
alive, 5 
deceased) 
 
2 participants - 
immigrant 
children 
No 
communication, 
few words 
 
Delayed early 
speech 
development in 
half of the 
sample 
 
Behavioural 
problems not 
defined 
Parent report 
and 
professional 
impression 
Behavioural 
problems 
suspected to be 
autism.  
Not formally 
diagnosed. 
 
 
Diagnoses of 
mental 
retardation by 6 
or 7 years old. 
Hyperactivity and 
developmental delay 
could cover an early 
normal development 
and misdirect any 
suspicion of a 
progressive disease 
 
Behaviour problems 
suspected to be autism 
or ADHD 
 
46% 
(Moderate) 
7 1 
 
B 
White female 
 
57 years old 
 
Non-
consanguineous 
family 
No peer 
interactions 
 
Repetitive 
 
Resisted 
physical contact 
 
Echolalia 
 
Unclear – not 
stated 
Reference to 
“autistic like 
features” 
 
Not formally 
diagnosed 
Focus on behavioural 
issues resulted in 
diagnosis at age 57 
years 
56% 
(Good) 
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Hypersensitivity 
to physical 
contact 
8 French 
sample -
128 
A- 87 
B- 18 
C – 17 
D – 6 
 
UK 
sample – 
126 
A -89 
B – 22 
C – 7 
D – 2 
Not 
determined 
– 6 
 
Greek 
sample – 
20 
B -16 
C – 3 
Not 
determined 
- 1 
111 French 30 
from multiplex 
families 
126 British 40 
from multiplex 
families 
 
20 Greek, no 
multiplex 
families 
France sample – 
language delay 
and ASD 
symptomology 
in: 
IIIA- 29% 
IIB – 19% 
IIIC – 8% 
IIID – 17% 
 
UK sample – 
85% had 
language delay 
and 66% ASD 
symptomology 
 
Greece sample 
– not stated 
Parental 
impression 
and reports on 
questionnaires 
Direct 
reference to 
ASD but not 
formally 
diagnosed 
Early diagnosis should 
be followed by early 
treatment when 
available 
50% 
(Good) 
  
 
 
30 
9 2 
 
B - 2 
White 
 
Females  
 
26 years & 31 
years 
 
Non-
consanguineous 
parents 
Participant 1 - 
Social 
immaturity 
 
Hyperactivity 
(preschool) 
 
Echolalia 
 
Participant 2 – 
mute 
Unclear – not 
stated 
Reports 
symptoms but 
no reference to 
ASD 
 
 
Participant 1 
was diagnosed 
with pervasive 
developmental 
disorder at age 
8 years  
MPS IIIB should be 
strongly considered in 
the differential 
diagnosis of patients 
with an early 
behavioural and 
psychiatric phenotype 
followed by 
progressive 
unexplained cognitive 
decline.   
Late diagnosis of MPS 
IIIB at age 26 years 
 
58% 
(Good) 
10 55 
 
A – 34 
B – 11 
C – 10 
 
Spanish 
 
28 female 
27 male 
 
Median age 13 
years 
 
Delayed speech 
in 85% by age 
18 months 
 
Hyperactivity in 
65% at mean 
age 3 years 
 
Lack of 
expressive 
language 
development 
Questionnaire 
(not specified) 
Reports 
symptoms but 
no reference to 
ASD 
Diagnostic delay was 
common, particularly 
in patients with a slow 
progression or 
attenuated phenotypes, 
especially in MPS IIIC 
 
Need for early 
diagnosis for family 
genetic counselling e.g. 
gene therapy and 
enzyme replacement 
therapy 
 
60% 
(Good) 
11 21 
 
A - 21 
14 male 
7 female 
 
Increased 
incidence of 
autistic like 
social 
ADOS  Reference to 
autistic like 
social 
behaviours 
A child exhibiting a 
lack of developmental 
gain or deceasing 
cognition coupled with 
62% 
(Good) 
  
 
 
31 
Mean age 4.5 
years 
 
behaviours 
emerging 
between 3-4 
years 
 
Few or no 
words 
 
 
 
13/21 met 
criteria for 
formal 
diagnosis of 
ASD 
 
All children 
aged over 3.8 
years met 
criteria and 2 
aged under 3.8 
years met 
criteria 
autistic like social 
behaviours should raise 
a red flag for MPS IIIA 
in differential diagnosis 
 
Symptoms of autism 
are characteristic of 
disease progression. 
Symptoms include a 
decrease in social 
communication 
 
Restricted interests and 
repetitive behaviours 
absent 
 
12 1 
 
A 
Male 
 
 
5 years old 
Non-
consanguineous 
parents 
Lack of speech 
notable at age 5 
years 
 
1st words at age 
18 months 
 
 
Parent report Refers to 
autism but no 
formal 
diagnosis 
Misdiagnosis of autism 
can occur 
 
Screen for MPS III in 
children with 
behavioural 
abnormalities and 
developmental delay 
 
47% 
(Moderate) 
13 2 
 
A-2 
Palestinian 
 
Females 
 
13 and 11 years 
old 
 
“Autistic 
features” in 
patient 1 
 
Speech delay in 
patient 2 and 
“autistic 
Parent and 
clinician 
impression 
Refers to 
“autistic 
features” in 
both 
participants but 
no formal 
diagnoses 
Misdiagnosis often 
occurs 
 
Autistic like features 
were found 
 
44% 
(Moderate) 
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Consanguineous 
Palestinian 
family 
features” (age 
18 months) 
Patients should go 
directly for genetic 
testing if presenting 
with similar features 
 
14 1 
 
* 
Female 
 
7 years old 
Reduced social 
interactions 
(age 6 years) 
 
Inability to 
understand 
speech (age 6 
years) 
 
Repeatedly 
clapped hands 
and hit head 
(from age 2 
years) 
 
Inability to 
understand and 
engage in 
routine social 
interactions 
(from age 2 
years) 
Parent and 
clinician 
impression 
Refers to ASD 
but no formal 
diagnosis 
 
Participant 
initially 
diagnosed with 
pervasive 
developmental 
disorder 
Autistic features are 
common with MPS 
IIIB 
 
Under diagnosis occurs 
 
Early diagnosis can 
improve chances of 
effectiveness of newer 
treatments 
 
MPS III should be 
considered in a child 
presenting with 
behavioural problems, 
who appears 
intellectually 
subnormal 
 
36% 
(Moderate) 
15 B - 10 White 
 
6 males 
4 females 
 
Impaired social 
communication 
 
Social/affective 
domain more 
ADOS 9/10 
participants met 
criteria for 
ASD on ADOS 
 
Phenotypic autistic like 
behaviours of both 
MPS IIIA and B may 
result in misdiagnosis 
 
74% 
(Good) 
  
 
 
33 
Mean age 16 
years 
  
affected than 
restricted or 
repetitive 
behaviours  
(over age 6 
years) 
 
MPS III B demonstrate 
symptoms associated 
with autism – impaired 
social communication 
 
Management 
techniques appropriate 
for ASD disorders 
might be appropriate 
for MPS III 
 
16 A Turkish 
 
Male 
 
7 years 
 
Non-
consanguineous 
parents 
Delayed speech 
 
Behavioural 
problems (not 
specified) aside 
from 
hyperactivity 
(from age 3 
years) 
Clinician 
impression 
 
Parent report 
Reports 
symptoms but 
no reference to 
ASD 
Initially diagnosed with 
ADHD 
 
Diagnostic process can 
be challenging and 
often protracted 
 
MPS III should be 
included in the 
differential diagnosis 
of developmental delay  
22% 
(Poor) 
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Table 3: Quality Ratings 
         
 
Item 
1 
 
Item 
2 
 
Item 
3 
 
Item 
4 
 
Item 
5 
 
Item 
6 
 
Item 
7 
 
Item 
8 
 
Item 
9 
 
Item 
10 
Item 
11 
 
Item 
12 
Item 
13 
Item 
14 
Item
15 
Item 
16 
Total raw score, 
average score (& % 
of highest possible 
score) 
Paper 1 2 1 1 1 3 1 0 1 0 0 N/A 1 1 N/A 0 1 13, 1 (31%) 
Paper 2 3 3 2 1 2 2 3 3 2 3 N/A 2 1 N/A 0 2 29, 2 (69%) 
Paper 3 1 3 2 N/A 1 2 1 1 N/A 3 2 0 N/A N/A 0 0 16, 1.3 (44%) 
Paper 4 3 3 2 1 2 1 1 1 1 2 N/A 2 0 N/A 0 2 21, 1.5 (50%) 
Paper 5 2 2 1 1 0 2 1 1 1 2 N/A 1 0 N/A 0 0 14, 1 (33%) 
Paper 6 2 3 2 2 2 2 1 1 0 2 2 2 0 0 0 1 22, 1.4 (46%) 
Paper 7 2 3 2 N/A 2 1 1 3 N/A 2 2 2 N/A N/A 0 0 20, 1.6 (56%) 
Paper 8 3 3 2 2 3 1 0 2 0 2 N/A 2 0 N/A 0 1 21, 1.5 (50%) 
Paper 9 3 3 3 N/A 1 2 1 1 N/A 3 2 2 N/A N/A 0 0 21, 1.8 (58%) 
Paper 10 3 3 1 2 2 2 1 3 1 2 N/A 3 1 N/A 0 1 25, 1.8 (60%) 
Paper 11 3 3 2 1 2 1 3 1 1 3 N/A 3 1 N/A 0 2 26, 1.9 (62%) 
Paper 12 2 3 3 N/A 1 1 0 1 N/A 2 2 1 N/A N/A 0 1 17, 1.4 (47%) 
Paper 13 3 1 3 N/A 1 1 0 2 N/A 1 2 2 N/A N/A 0 0 16, 1.3 (44%) 
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(0 = not at all, 1 = very slightly, 2 = moderately, 3 = complete) 
 
Item 1 – Explicit theoretical framework  
Item 2 – Statement of aims/objectives 
Item 3 – Clear description of research setting 
Item 4 – Evidence of sample size considered in terms of analysis 
Item 5 – Representative sample of target group of a reasonable size 
Item 6 – Description of data collection procedure 
Item 7 – Rationale for choice of data collection tools 
Item 8 – Detailed recruitment data 
Item 9 – Statistical assessment of reliability and validity (Quantitative only) 
Item 10 – Fit between stated research question and method of analysis 
Item 11 – Fit between stated research question and content of data collection (Qualitative) 
Item 12 – Ft between research question and method of analysis 
Item 13 – Good justification for analytical method selected 
Item 14 – Assessment of reliability of analytical process (Qualitative only) 
Item 15 – Evidence of service user involvement in design 
Item 16 – Strengths and limitations critically discussed 
 
Table 3 continued 
 
Item 
1 
Item 
2 
Item 
3 
Item 
4 
Item 
5 
Item 
6 
Item 
7 
Item 
8 
Item 
9 
Item 
10 
Item 
11 
Item 
12 
Item 
13 
Item 
14 
Item 
15 
Item 
16 
Total raw score, 
average score (& % 
of highest possible 
score) 
Paper 14 2 2 3 N/A 1 2 0 1 N/A 0 1 1 N/A N/A 0 0 13, 1 (36%) 
Paper 15 3 3 3 2 1 2 3 3 1 2 N/A 3 3 N/A 0 2 31, 2.2 (74%) 
Paper 16 1 1 1 N/A 1 1 0 1 N/A 0 1 1 N/A N/A 0 0 8, 0.6 (22%) 
